Non-nociceptive environmental stress induces hyperalgesia, not analgesia, in pain and opioid-experienced rats.
It is well admitted that stress induces analgesia (SIA) via endogenous opioid release. However, there is evidence that stressful events play a role in the pathogenesis of pain, but little is known about mechanisms underlying such pain vulnerability. Previous studies reported that a single opioid exposure activates NMDA-dependent pronociceptive systems leading to long-term pain vulnerability after analgesia. Here, we studied whether prior inflammatory pain or/and opioid experiences may favour the development of pain vulnerability after non-nociceptive environmental stress (NNES). Nociceptive threshold (NT) changes were evaluated by paw pressure vocalization test. By contrast to discrete SIA observed in naive rats, 1 h stress induced hyperalgesia (SIH) for several hours (15-65% NT decrease) in pain and opioid experienced rats. Repetition of NNES induced an 18- to 22-fold SIH enhancement (3-4 days), whereas SIA decreased. SIH was still observed 4 months after pain and opioid experiences. This phenomenon is referred to as latent pain sensitization. Furthermore, a fentanyl ultra-low dose (ULD, 50 ng/kg) administration, mimicking SIA in naive rats, induced hyperalgesia (65% NT decrease, 4 h), not analgesia, in pain and opioid-experienced rats. This indicates that low levels of opioids induce opposite effects, that is analgesia vs hyperalgesia dependent on prior life events. In pain and opioid-experienced rats, NMDA receptor antagonists, ketamine or BN2572, completely prevented hyperalgesia when injected just before NNES or fentanyl ULD. This latent pain sensitization model may be important for studying the transition from acute to chronic pain and individual differences in pain vulnerability associated with prior life events.
Rivat
Cyril
C
Laboratoire Homéostasie-Allostasie-Pathologie, Université Victor Ségalen Bordeaux 2, Bordeaux 33076, France.
Laboureyras
Emilie
E
Laulin
Jean-Paul
JP
Le Roy
Chloé
C
Richebé
Philippe
P
Simonnet
Guy
G
D000701:Analgesics, Opioid / Q000009:adverse effects; D000818:Animals; D001923:Brain Chemistry / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005283:Fentanyl / Q000009:adverse effects; D006930:Hyperalgesia / Q000209:etiology* / Q000503:physiopathology*; D008297:Male; D008568:Memory / Q000502:physiology*; D018847:Opioid Peptides / Q000378:metabolism*; D010147:Pain Measurement / Q000379:methods; D017288:Pain Threshold / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors / Q000378:metabolism; D011957:Receptors, Opioid / Q000187:drug effects / Q000378:metabolism; D013315:Stress, Psychological / Q000150:complications* / Q000503:physiopathology*
D000701:Analgesics, Opioid; D018691:Excitatory Amino Acid Antagonists; D018847:Opioid Peptides; D016194:Receptors, N-Methyl-D-Aspartate; D011957:Receptors, Opioid; D005283:Fentanyl